Feature | Contrast Media Injectors | March 02, 2017 | By Jeff Zagoudis

Advances in Contrast Media Injector Technology

This article originally was published as an introduction to the Contrast Media Injectors comparison chart published in the March 2017 issue.

contrast media

With medical imaging use on the rise, contrast media use is expected to grow as well, according to a May 2016 report from market research firm GlobalData. According to the report, the global market value for contrast injectors was $830 million in 2015, and that number is expected to reach nearly $1.8 billion by 2022 — an increase of nearly $970 million in just seven years. The growth will largely be driven by increasing use of computed tomography (CT), magnetic resonance imaging (MRI) and angiography procedures, as well as increasing disease burdens, according to GlobalData.

In the United States, healthcare reform has been another major driver of innovation. Reform efforts such as the Medicare Access and CHIP Reauthorization Act (MACRA) are poised to alter the way clinicians are reimbursed, providing incentives for them to practice more efficient, value-based care and evaluating their performance based on the quality of care delivered. In the world of contrast injectors, this is spurring increased adoption of technologies like syringeless injectors, which can improve imaging exam efficiency, and contrast dose recording systems, which can serve as a mechanism for measuring quality of care. 

 

Syringeless Injectors 

Syringeless power injectors have emerged in recent years as a solution to reduce contrast media waste. The Joint Commission does not allow the reuse of unused doses from single-use syringe injectors, so this option gives facilities the opportunity to use contrast media as efficiently as possible. Syringeless injectors have also been demonstrated to reduce exam times, leading to increased patient throughput. A study published in the Journal of the American College of Radiology in 2012 compared the efficiency of a dual-syringe injector with a syringeless injector in 275 consecutive CT exams. The syringeless injector saved over 2 minutes per exam, resulting in an increased throughput of 2.6 patients per day.1 

The first syringeless injector on the U.S. market, Bracco’s CT Exprès 3-D, launched at the 2016 Radiological Society of North America (RSNA) annual meeting in November. The multi-dose delivery system is designed for multi-patient use to increase the number of scans clinicians can perform in a day. The system is used in combination with the Isovue Imaging Bulk Package (IBP) and saline (0.9 percent sodium chloride injection USP). IBP was recently defined by the United States Pharmacopeia as the only contrast medium container for multi-dose, multi-patient use directly in the radiology room. 

Bracco is releasing its SmartInjectCT Solution, a dual offering of EmpowerCTA+ Injector System and NEXO Contrast Management System, in February 2017. SmartInjectCT Solution helps automated compliance to dose documentation guidelines, has enterprise-wide protocol management, and fleet-wide advancement in automation and documentation. EmpowerCTA+ Injector System, launched in March 2015, is indicated for the vascular administration of contrast and flushing media in conjunction with computed tomography (CT) scanning of the body with an optional interface to a CT scanner and an optional calculator for glomerular filtration rate (GFR). The EmpowerCTA+ allows users to fully customize the injection experience for each patient with real-time variable flow rates, Saline Advance and Saline Jump; Saline Advance feature can be used to test vein patency before performing the injection, while Saline Jump may be used in the last contrast injection phase, causing the system to immediately stop injecting contrast medium and jump to the programmed saline injection phase.

Bracco’s EmpowerCTA+ systems are supported by the Nexo Contrast Management System, which automatically delivers all the injection information to a centralized server. This allows for enterprise-wide contrast dose management.

Guerbet launched its syringe-free injection system, FlowSens, in March 2014. Composed of a softbag injector and associated disposables, the system uses a hydraulic, syringe-free injector to deliver contrast media. It is compatible with the company’s ScanBag solution and any type of contrast agent available on the market.

 

Dose Recording Systems 

While medical imaging and contrast use are on the rise, several recent studies have raised concerns about potential lingering effects of contrast agents, particularly gadolinium. As a result, several vendors offer their own methods of recording contrast dose and sending the information directly to a picture archiving and communication system (PACS), electronic medical record (EMR) or other data storage system.  

Bracco’s EmpowerCTA systems are supported by the Nexo Contrast Dose monitoring solution, which automatically delivers all injection information to a centralized server. This allows for enterprise-wide injector management. According to Bracco, Nexo has the ability to capture four Improvement activity measures under the Merit-based Incentives Payment System (MIPS), one of the two new alternative reimbursement tracks offered under MACRA.

Medrad most recently released version 2.5 of the Radimetrics Enterprise Platform at RSNA 2014. The latest release of Radimetrics features more advanced contrast dose analytics, with new charts and data options to help identify repeat injections and issues associated with intravenous administration. The platform is integrated onto several of Medrad’s systems, including the MR Xperion. 

Mallinckrodt launched its own contrast dose monitoring solution, the OptiSync data management system, in the fall of 2014 to complement its OptiVantage dual-head CT contrast delivery system. Operators can access all patient and pharmaceutical information with the scan of a barcode, and injection data — including the patient, drug, dose and administration — is transmitted to HL7-based healthcare systems while patient records are automatically updated. This creates a shared facility database that can help users assess areas where they can reduce errors, increase productivity or improve efficiency.

 

Other Recent System Releases

In February 2016, Guerbet announced U.S. Food and Drug Administration (FDA) clearance for the OptiOne single-head contrast delivery system. OptiOne is manufactured by Liebel-Flarsheim, one of the companies Guerbet acquired in November 2015 when it purchased Mallinckrodt’s Contrast Media and Delivery Systems (CMDS) business. The entry-level single-head injector is designed for injection of radiopaque CT contrast agents into the vascular system. It uses a motor-driven syringe mechanism with microprocessor control of the flow rate, volume, pressure and timing. All operations are performed on the touch-screen console, and the system has the ability to accommodate prefilled or empty syringes. 

Reference

1.    Ma, X., Singh, A., Fay, J., Boland, G., et al. “Comparison of Dual-Syringe
    and Syringeless Power Injectors in Outpatient MDCT Practice:
    Impact on the Operator’s Performance, CT Workflow, and Operation
    Cost.” Journal of the American College of Radiology. Published
    Aug. 2012. 

Related Content

Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI

Getty Images

News | Contrast Media Injectors | September 16, 2021
September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthc
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

News | PET-CT | August 04, 2021
August 4, 2021 — PET/CT systems are exp
According to ARRS’ American Journal of Roentgenology (AJR), the resources required to warm iohexol 350 to body temperature before injection for computed tomography (CT) may not be warranted, given the lack of observed practical benefit.

Values represent number of patients, with percentage in parentheses and 95% CI in brackets (not reported for levels of severity of allergic/allergic-like reactions). 95% CIs were calculated using the Clopper-Pearson exact formula. For events with zero frequency, one-sided 97.5% CIs are provided.

News | Contrast Media | July 30, 2021
IQ-AI subsidiary Imaging Biometrics (IB) was awarded a U.S. patent for its artificial intelligence (AI) software technology that eliminates the need for gadolinium-based contrast agents (GBCAs) in medical imaging exams.
News | Contrast Media | June 30, 2021
June 30, 2021 – IQ-AI subsid
The contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement

image courtesy of Guerbet

News | Contrast Media | May 03, 2021
Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or
Gadopiclenol is a high-relaxivity macrocyclic contrast agent used for magnetic resonance imaging (MRI)
News | Contrast Media | March 24, 2021
March 24, 2021 — Guerbet announced positive results from two...
(a) High-resolution 3D MRI brain vascular map using SAIO. Various blood vessels in the rat brain can be visualized. In addition to clinically important brain vessels including anterior cerebral artery, middle cerebral artery, posterior cerebral artery, fine vessel structures as thin as ~ 100 microns in diameter can be clearly visualized. (b) 3D MRI brain vascular map using Dotarem (gadolinium-based contrast agent). Resolution is low and microvessels are not visible. (c) For 3D reconstruction, multiple slice

(a) High-resolution 3D MRI brain vascular map using SAIO. Various blood vessels in the rat brain can be visualized. In addition to clinically important brain vessels including anterior cerebral artery, middle cerebral artery, posterior cerebral artery, fine vessel structures as thin as ~ 100 microns in diameter can be clearly visualized. (b) 3D MRI brain vascular map using Dotarem (gadolinium-based contrast agent). Resolution is low and microvessels are not visible. (c) For 3D reconstruction, multiple slices of MRI images of the rat heart were obtained after injection of SAIO. Rat coronary arteries (180 microns) which are 10 times thinner than human coronary arteries were successfully visualized. Coronary arteries supply blood to the heart muscle and the blockage or narrowing of such arteries causes myocardial infarction or angina, but visualizing these arteries was impossible due to the limited resolution of current MRI contrast agents. Image courtesy of Institute for Basic Science

News | Contrast Media | March 12, 2021
March 12, 2021 — Heart attack and stroke are the first and second leading causes of death in developed countries, res
Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...